<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672020</url>
  </required_header>
  <id_info>
    <org_study_id>NI14028</org_study_id>
    <secondary_id>PRTK-14-079</secondary_id>
    <nct_id>NCT02672020</nct_id>
  </id_info>
  <brief_title>Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card</brief_title>
  <acronym>COMETETACTIC</acronym>
  <official_title>The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two
      rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers
      improved thanks to the French COMETE network originally based on two clinical centers (HEGP
      and Cochin) well organized for clinical and biological samples collection. Over the last 10
      years, the COMETE key partners deciphered molecular mechanisms of tumorigenesis and
      oncogenesis of these tumors and identified molecular signatures discriminating between benign
      and malignant cancers by integrated genomic approaches. This strategy was highly successful
      in delivering new diagnostic applications of genomics technologies that now appear as
      potentially suitable for rapid implementation in routine clinical care.

      The main objective of COMETE-TACTIC is to provide an easy-to-use &quot;identity card&quot; of the
      adrenal tumors that will allow a personalized &quot;à la carte&quot; management of the patient and,
      when indicated, to the indication of the most accurate molecular targeted therapy.

      We hypothesize that the improvement of MPP and ACC diagnosis and of the therapeutic options
      proposed to affected patients will require,

        1. the transfer to routine practice and the prospective validation of the novel diagnostic
           and predictive biomarkers issued from recent discoveries (genetics, genomics,
           histological biomarkers);

        2. the implementation of the translational research projects based on the COMETE collection
           to identify circulating diagnostic, prognostic and therapeutic genetic and metabolic
           biomarkers that could be used as non-invasive &quot;liquid biopsies&quot;.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two
      rare cancer entities with a very unfavorable prognosis. The knowledge on these rare cancers
      improved thanks to the French COMETE ('COrtex, MEdulla Tumors Endocrines') network originally
      based on two clinical centers (HEGP and Cochin) well organized for clinical and biological
      samples collection. Over the last 10 years, the COMETE key partners deciphered molecular
      mechanisms of tumorigenesis and oncogenesis of these tumors and identified molecular
      signatures discriminating between benign and malignant cancers by integrated genomic
      approaches. COMETE has published more than 200 papers and performed seminal work on the
      pathophysiology and the genetics of MPP and ACC published in high-impact journals.

      This strategy was highly successful in delivering new diagnostic applications of genomics
      technologies that now appear as potentially suitable for rapid implementation in routine
      clinical care.

      The main objective of COMETE-TACTIC program is to design and validate an easy-to-use
      &quot;identity card&quot; classifying MPP and ACC in clinical routine, using molecular genomic and
      metabolomic tools combined with histopathological-based tests, to provide a real help for
      early diagnosis, prognostic as well as a personalized &quot;à la carte&quot; management and treatment
      to patients with malignant adrenal tumors. Seven teams, with an expertise in genomics of
      adrenal tumors, or in metabolomics approaches, or in clinical research and statistical
      analyses collaborate in COMETE-TACTIC. COMETE-TACTIC will be based on an already constituted
      large cohort of 850 patients that will be enlarged by the prospective enrolment of new cases
      and biological samples (300 to 450 new cases during the 3 years of the project) via 21 French
      expert and/or competence centers of COMETE-Cancer Reference center.

      Previous COMETE basic studies provided important new insight for the understanding of
      molecular mechanisms responsible for MPP or ACC. With the transfer of &quot;Omics&quot;-based tests
      from research laboratories to clinical practice, COMETE-TACTIC is the next step toward a
      personalized medicine for patients with MPP and ACC. COMETE-TACTIC should speed the transfer
      in routine clinical care of new biomarkers based on cutting-edge technologies combining
      advanced pathology assessment and targeted genomics and metabolomics to diagnose malignancy
      and predict outcome, and thereby facilitating a more accurate, rapid and reliable diagnostic
      work-up for patients. This personalized management will help to avoid delayed diagnosis and
      to direct clinical decisions resulting in a better health outcome for the patients.
      COMETE-TACTIC will offer the access to a precise molecular classification of MPP and ACC that
      should guide targeted therapies. Finally, COMETE-TACTIC will investigate for the first time
      the impact of circulating biomarkers for the diagnosis and prognostic of adrenal cancers that
      will be further tested as biomarkers of response to targeted therapies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">March 26, 2019</completion_date>
  <primary_completion_date type="Actual">March 26, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malignant status</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Number of participants with evidence of metastases</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">448</enrollment>
  <condition>Adrenal Gland Neoplasms</condition>
  <arm_group>
    <arm_group_label>patients with adrenal tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>omics identity card</intervention_name>
    <arm_group_label>patients with adrenal tumor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient operated on a tumor developed from the adrenal cortex or a pheochromocytoma or
             a paraganglioma

          -  Age≥15 years

          -  Signature of the informed consent

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne-Paule GIMENEZ-ROQUEPLO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux de Paris-HEGP, Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU-Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen-Hopital de Bois-Guillaume</name>
      <address>
        <city>Bois-Guillaume</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux, Hopital du Haut Leveque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Brest, Hopital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL- Centre Hospitalier Lyon Est</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand, Hopital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble- Hopital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Pais, Hopital de Bicetre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Limoges, Hopital du Cluzeau</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier, Hopital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nantes, Hopital Laënnec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Paris -HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Paris, Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Paris, Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Paris, Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims, Hopital Robert Debre</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes, Hopital Sud</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Strasbourg, Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse, IUC Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Tours, Hopital Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Castro-Vega LJ, Letouzé E, Burnichon N, Buffet A, Disderot PH, Khalifa E, Loriot C, Elarouci N, Morin A, Menara M, Lepoutre-Lussey C, Badoual C, Sibony M, Dousset B, Libé R, Zinzindohoue F, Plouin PF, Bertherat J, Amar L, de Reyniès A, Favier J, Gimenez-Roqueplo AP. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015 Jan 27;6:6044. doi: 10.1038/ncomms7044.</citation>
    <PMID>25625332</PMID>
  </reference>
  <reference>
    <citation>Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C, Janin M, Menara M, Nguyen AT, Benit P, Buffet A, Marcaillou C, Bertherat J, Amar L, Rustin P, De Reyniès A, Gimenez-Roqueplo AP, Favier J. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell. 2013 Jun 10;23(6):739-52. doi: 10.1016/j.ccr.2013.04.018. Epub 2013 May 23.</citation>
    <PMID>23707781</PMID>
  </reference>
  <reference>
    <citation>Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, Rodriguez S, Perlemoine K, René-Corail F, Elarouci N, Sbiera S, Kroiss M, Allolio B, Waldmann J, Quinkler M, Mannelli M, Mantero F, Papathomas T, De Krijger R, Tabarin A, Kerlan V, Baudin E, Tissier F, Dousset B, Groussin L, Amar L, Clauser E, Bertagna X, Ragazzon B, Beuschlein F, Libé R, de Reyniès A, Bertherat J. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014 Jun;46(6):607-12. doi: 10.1038/ng.2953. Epub 2014 Apr 20.</citation>
    <PMID>24747642</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pheochromocytoma</keyword>
  <keyword>paraganglioma</keyword>
  <keyword>adrenocortical carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

